AzTrials
AzTrials

Gastrointestinal NeoplasmsNCT04361227

Utility of OverStitch Sx After ESD

An observational study of Gastrointestinal Neoplasms, run by Baylor College of Medicine at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is a prospective study where the investigators will make a database of all the patients who have received this procedure and will document various outcomes (i.e. number of sutures used, number of clips (if used), time required to close, complications/ issues). Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Gastrointestinal Neoplasms
How many people
33 participants
Where
1 siteUnited States
Study dates
2 Jul 2020to 20 Oct 2022
How long will I take part?
48 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients referred to/scheduled for ESD procedure at Baylor College of Medicine with possible mucosal defect closure.

Who may be able to join

  • Adults age 18-99, who are scheduled to undergo ESD procedure with possible mucosal defect closure.

Who cannot join

  • Age is less than 18 years old

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Baylor College of Medicine

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: Prospective Study of Utility of OverStitch Sx Endoscopic Suturing System After ESD Procedure

This study is a prospective study where the investigators will make a database of all the patients who have received this procedure and will document various outcomes (i.e. number of sutures used, number of clips (if used), time required to close, complications/ issues). No changes will be done to the participant's procedure and the participants are asked to consent for the use of the participant's data in our database. The participants are being asked to be in this research study because the participants have been scheduled to undergo an ESD procedure at Baylor St. Luke Medical Center and will most likely require clipping and/or suturing following intervention. This study is important because this is a relatively new procedure; although it is a part of the participant's standard of care, it is not done in many hospitals. The investigators would like to document the outcomes and results of such procedures to continuously improve our standard of care.

Read the detailed description

Resection of gastrointestinal neoplastic lesions at an early stage has been associated with improved clinical outcomes. While surgery has been traditionally performed for the resection of these precancerous or cancerous lesions confined to the mucosa of the GI tract, it is often associated with a higher morbidity and mortality rate compared to alternative endoscopic therapies. Recently, endoscopic submucosal dissection (ESD) has emerged as a new endoscopic technique that allows en-bloc resection of GI lesions, irrespective of size. In comparison to other endoscopic techniques, such as endoscopic mucosal resection (EMR), ESD is associated with higher curative resection rates and lower recurrence. While ESD was initially developed for the treatment of gastric cancer in Asia, which is relatively rare in the West, this technique would intuitively seem suitable for the resection of other superficial neoplastic lesions in the GI tract (i.e. large colon polyps, Barrett's mucosa, early non-invasive cancer). With the differences in patient population and disease location one can anticipate some differences in outcomes between ESD performed in Asian and US patients. Endoscopic Submucosal Dissection (ESD) is considered the gold standard for removal of pre-cancerous lesions from the GI tract, as histological analysis is more definitive, and the recurrence rate is lower as compared to endoscopic mucosal resection (EMR).

While ESD is useful for therapeutic and diagnostic purposes, the technique is rather difficult and detailed requiring extended procedure times. The most common complications of the ESD techniques are bleeding and perforation. Other rare complications include aspiration pneumonia, air embolisms, or stenosis. For this reason, closure of the mucosa following an endoscopic resection became an area of increased interest.

A randomized study in October of 2019 examined if prophylactic closure of a mucosal defect with clips would reduce the risk of bleeding following endoscopic intervention by EMR. 919 patients were randomly assigned to groups with 3.5% of patients experiencing post-procedure bleeding compared to 7.1% within the control group. Through this randomized trial, they found a significant reduction in post-procedural bleeding when patients undergo endoscopic clip closure of the mucosal defect.

With the advancements in endoscopic therapy, post-procedural clipping is now a well-established means of treatment following mucosal resections. Clipping, however, has two limitations including their inability to close large defects and the increasing difficulty in removal of those clips. To address these issues, endoscopic suturing systems have been developed which simulate the effectiveness of surgical stitching. The OverStitch Sx (Apollo Endosurgery Inc.) is commercially available and widely used in various applications such as the fixation of esophageal stents, suturing of ulcers, or reduction of anastamoses in bariatric surgeries.

Kantsevoy et al. in a 2014 retrospective study has shown that large mucosal defects treated with endoscopic suturing following an ESD resulted in a decrease rate of adverse events as well as the need for hospitalizations. All patient lesions were successfully and completely closed with no delayed or immediate adverse events following the procedure. The study concludes that the use of the Overstitch Sx device is fast and feasible and can decrease treatment costs by reducing the need to hospitalize patients.

Keywords
Gastrointestinal Neoplasms, OverStitch Sx, Endoscopic Submucosal Dissection
Medical subject headings
Gastrointestinal Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical/technical success rate utilizing endosuture

    To assess feasibility and technical success of using Overstitch Sx system for closure after ESD

    Measured: 2 years

  2. Rate of patients reported with bleeding/perforation post-ESD procedure

    Conduct follow-ups for risk of bleeding and perforation after closure

    Measured: 2 years

  3. Closure time after ESD

    Record time needed to close lesion

    Measured: 2 years

Secondary outcomes (2)
  1. Additional clip closure

    Identify, if any, need for additional clipping after endoscopic suture closure

    Measured: 2 years

  2. Clips used post-ESD

    Record number of sutures needed to close lesion

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2020
  2. Study start2 Jul 2020
  3. Primary completion31 May 2022
  4. Study completion20 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
33 participants (actual)
Target duration
48 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04361227
Sponsor's protocol ID
H-47184
Status last verified
Feb 2023
First submitted
22 Apr 2020
Last updated
15 Feb 2023
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided: Study is currently considered as a single-center prospective study.

Publications

  • Keihanian T, Zabad N, Khalaf M, Abdel-Jaber W, Kim YI, Jawaid SA, Abidi WM, Marginean EC, Othman MO. Safety and efficacy of a novel suturing device for closure of large defects after endoscopic submucosal dissection (with video). Gastrointest Endosc. 2023 Sep;98(3):381-391. doi: 10.1016/j.gie.2023.04.006. Epub 2023 Apr 14.

    PubMed 37061137

Questions about this trial

What is this clinical trial studying?

An observational study of Gastrointestinal Neoplasms, run by Baylor College of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical/technical success rate utilizing endosuture (time frame: 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04361227, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in